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Ian M. Loftus, MD, FRCS, Matt M. Thompson, MD, FRCS, and Robert J. Hinchliffe, MD, FRCS,
London, United Kingdom
Objective: The objective of this study was to provide a systematic review and meta-analysis of outcomes of infrainguinal
angioplasty with drug-eluting stent (DES) or balloon (DEB).
Methods: The EMBASE, MEDLINE, and Cochrane databases and the Current Controlled Trials register were system-
atically interrogated for articles reporting results of infrainguinal angioplasty with DESs or DEBs. Clinical and angio-
graphic end points were included.
Results: The review included 26 studies that reported on 2407 limbs; 11 were prospective randomized controlled trials.
Infrapopliteal angioplasty with DEB was reported in 109 limbs (claudication, 19; critical limb ischemia [CLI], 90) (limb
salvage in CLI, 95.6%; target lesion revascularization [TLR], 17.3%; mortality, 16%; mean follow-up, 12.3 months).
Infrapopliteal angioplasty with DES was reported in 882 limbs (claudication, 160; CLI, 590; unclear severity, 132) (limb
salvage in CLI, 97.4%, TLR, 10.8%; mortality, 17%; mean follow-up, 22.9 months). Femoropopliteal angioplasty with
DES was reported in 1174 limbs (claudication, 301; CLI, 58; unclear severity, 815) (limb salvage in CLI, 89.6%; TLR,
17.3%; mortality, 3%; mean follow-up, 10.6 months). Femoropopliteal angioplasty with DEB was reported in 242 limbs
(claudication, 182; CLI, 12; unclear severity, 48) (TLR, 10.6%; mortality, 2%; mean follow-up, 11 months). Meta-
analysis of studies comparing DEB with standard balloon angioplasty demonstrated a result in favor of DEBs for pre-
venting binary primary restenosis (odds ratio [OR], 0.27; P[ .005) and TLR (OR, 0.17; P[ .001). The meta-analysis
comparing DESs with bare-metal stents demonstrated a result in favor of DES with regard to preventing TLR (OR, 0.15;
P[ .001) and binary primary restenosis (OR, 0.23; P[ .001). Drug-eluting technology did not prevent more deaths or
amputations.
Conclusions: Early angiographic data suggest that drug-eluting devices prevent restenosis in the short term, but there is as
yet no evidence of an increase in limb salvage rates or a reduction in mortality. Further large randomized controlled trials
with a focus on clinical outcomes and longer follow-up are needed. (J Vasc Surg 2014;59:1721-36.)Endovascular revascularization by balloon angioplasty
is widely used in everyday clinical practice for the treatment
of critical limb ischemia (CLI) due to infrainguinal athero-
sclerotic disease.1 The BASIL (Bypass vs Angioplasty in Se-
vere Ischaemia of the Leg) study compared percutaneous
angioplasty with surgical bypass for treatment of severe
lower limb ischemia in patients considered suitable for
either approach.2 After 2 years, both approaches achieved
therapeutic equipoise with regard to amputation and sur-
vival. However, the major limitation of balloon angioplasty
remains its durability, especially in treatment of below-the-
knee lesions. A meta-analysis has demonstrated a 1-year
primary patency of only 58% after crural angioplasty.3the St George’s Vascular Institute, St George’s Healthcare NHS
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://dx.doi.org/10.1016/j.jvs.2014.03.235In an attempt to improve the durability of endovascular
therapy, bare-metal stents (BMSs) have been developed
but have been complicated by signiﬁcant rates of stent
thrombosis and neointimal hyperplasia. These problems
have prompted the introduction of drug-eluting endovas-
cular technology, initially developed for the coronary
circulation. These technologies are designed to deliver anti-
proliferative drugs to the local vessel wall in an attempt to
reduce restenosis.
Drug-eluting stents (DESs) were initially and subse-
quently widely used for coronary artery lesions.4 The initial
enthusiasm with DESs has been tempered by their draw-
backs, including late stent thrombosis, need for prolonged
dual antiplatelet therapy, and persistent restenosis.5 The
aim of this review was to collect all current published evi-
dence regarding the role of angioplasty with use of drug-
eluting balloons (DEBs) and DESs for infrainguinal arterial
disease.
METHODS
A systematic review was performed by use of the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines.6
Search strategy. A literature search was undertaken to
identify all published English-language studies reporting
results of infrainguinal angioplasty with DEBs and DESs.
The EMBASE, MEDLINE, and Cochrane databases for1721
Table I. Assessment of methodologic quality and risk of bias in controlled studies
Study
Adequate sequence
generation
Allocation
concealment Blinding
Incomplete outcome
data addressed
Free of selective
reporting
Free of
other bias
Duda25 ? ?  Angiographic outcomes
þ Clinical outcomes
  
Duda26 ? ?  Angiographic outcomes
? Clinical outcomes
  
Scheinert13 NA NA þ   
Bosiers21 ? ?  þ  
Dake28   þ þ  
Rastan20  ? þ þ  
Scheinert22  ? þ þ  
Tepe9  ? þ   
Tepe33 ? ? þ þ  
Werk10 ? ? þ   
Falkowski31  ? þ   
Siabilis32 NA NA þ   
Werk30      
þ, High risk of bias; ?, unclear risk of bias; , low risk of bias; NA, not applicable.
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Controlled Trials register were searched. Key words
entered in this search were ‘‘drug-eluting stent’’ or ‘‘drug-
eluting balloon,’’ ‘‘femoropopliteal arteries,’’ ‘‘below-the-
knee arteries,’’ and ‘‘angioplasty,’’ with the Boolean oper-
ator odds ratio (OR). The reference lists of the articles ob-
tained were reviewed for pertinent citations. Articles were
excluded if they assessed the use of adjunctive procedures
(laser, ultraviolet, or cryotherapy angioplasty) or pooled re-
sults, preventing analysis by segment of vessel treated.
Studies were not excluded on the basis of disease severity.
When studies contained duplicate data, the paper with
the most up-to-date or best documented material was used
for analysis.
Data extraction. Data were extracted by two authors
(L.C., B.O.). Studies were separated into four groups for
the purpose of analysis:
Patients treated for infrapopliteal lesions with DEB
angioplasty
Patients treated for femoropopliteal lesions with DEB
angioplasty
Patients treated for infrapopliteal lesions with DESs
Patients treated for femoropopliteal lesions with DESs
Four groups were used for the meta-analysis:
Studies comparing DES with BMS (pooled femoropo-
pliteal and infrapopliteal)
Studies comparing DES with BMS (femoropopliteal)
Studies comparing DES with BMS (infrapopliteal)
Studies comparing DEB with standard percutaneous
angioplasty (SPTA) (femoropopliteal)
Studies were assessed for methodologic quality and risk
of bias by the guidelines outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions.7 These guide-
lines classify studies as at high, unclear, or low risk of bias
with regard to adequacy of sequence generation, allocation
concealment, blinding, accounting/addressing for incom-
plete data, freedom from selective reporting, and other
biases. Data were extracted for study design; clinicaloutcomesdimprovement in intermittent claudication,
wound healing, major amputation (above ankle), limb
salvage (deﬁned as freedom from major amputation),
amputation-free survival (deﬁned as freedom from major
amputation and death), and death; and angiographic
outcomesdprocedural technical success, binary primary
restenosis, primary patency, late lumen loss (LLL), and
target lesion revascularization (TLR). In studies comparing
DEB with SPTA, additional intraoperative stenting of the
target lesion after angioplasty was considered a technical
failure.
Statistical analysis. Results quoted in the text refer
to mean with range unless otherwise speciﬁed. The meta-
analysis was performed with Review Manager version
5.2 (Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2012). ORs and 95% conﬁ-
dence intervals (CIs) were calculated by the method
of Mantel-Haenszel. Heterogeneity was assessed with the
I2 method. A ﬁxed-effects model was used unless calculated
I2 was $25%.
RESULTS
Overall
We screened the title and abstract of 2241 potentially
eligible publications. Of these, 2191 citations were
excluded because they were not relevant to this study. Of
the 50 studies further assessed for eligibility, 26 met the in-
clusion criteria, of which 11 were prospective randomized
controlled trials and two were cohort studies with con-
trols.8-33 With two exceptions, all studies used the
Rutherford-Baker classiﬁcation of ischemia.15,17 Only two
studies applied both the guidelines of the Society for
Vascular Surgery Ad Hoc Committee for reports dealing
with extremity ischemia and the European consensus rec-
ommendations for reports of endovascular treatment for
chronic lower limb ischemia.21,29 Table I summarizes the
results of the quality assessment of the included controlled
Table II. Study design and characteristics of patients and lesions of included studies of angioplasty with drug-eluting
balloon (DEB)
First
author Year
Study
design
Patients,
No.
Limbs
treated,
No.
CLI,
%
Diabetes
mellitus,
%
Renal
insufﬁciency,
% TASC
Lesion
type,
drug-eluting
arm
Disease
length,
drug-eluting
arm, mm
Lesion
type,
standard
arm
Disease
length,
standard
arm, mm
Follow-up,
months
Schmidt8 2011 Case series,
DEB
104 109 82.6 71.2 46.2 No data Not speciﬁed 176 NA NA 12.3 6 1
Tepe9 2008 Randomized
controlled
trial, DEB
vs SPTA
102 102 d 38 d No data Mixed de novo,
restenotic
after SPTA,
with stenting
8 (17%) and
without
stenting 10
(21%) and
occlusions 13
(27%)
75 Mixed de novo,
restenotic
after SPTA,
with stenting
6 (11%) and
without
stenting 10
(19%) and
occlusions
14 (26%)
74 11.8
Werk10 2008 Randomized
controlled
trial, DEB
vs SPTA
87 87 74 40 d TASC II
DEB: 14/45 A,
11/45 B,
16/45 C,
4/45 D
SPTA: 21/42 A,
4/42 B,
10/42 C,
7/42 D
Mixed de novo,
restenotic
after SPTA,
with stenting
14 (31%) and
without
stenting 2
(4%) and
occlusions 6
(45%)
40 Mixed de novo,
restenotic
after SPTA,
with stenting
8 (19%) and
without
stenting 10
(24%) and
occlusions
4 (10%)
47 7.2
Micari11 2012 Case series,
DEB
105 105 72.4 51 2 No data 109/114 de
novo
4/114 restenotic
1/114 in-stent
restenosis
34/114 total
occlusions
176 NA NA 11.7
Werk30 2012 Randomized
controlled
trial, DEB
vs SPTA
85 91 4.4 35 0 No data Mixed de novo,
restenotic
after SPTA,
with stenting
7 (16%) and
without
stenting 7
(16%) and
occlusions 10
(23%)
70 Mixed de novo,
restenotic
after SPTA,
with stenting
6 (13%) and
without
stenting 2
(4%) and
occlusions 18
(38%)
66 12
CLI, Critical limb ischemia; NA, not applicable; SPTA, standard percutaneous angioplasty; TASC, TransAtlantic Inter-Society Consensus.
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unclear risk of bias with regard to adequate sequence gen-
eration (5 of 11), allocation concealment (9 of 11), and
blinding (11 of 13 for clinical outcomes, 6 of 12 for angio-
graphic outcomes). The radiographic appearance of some
DESs differs signiﬁcantly from that of BMSs, and therefore
blinding of several studies was uncertain. No study
adequately prespeciﬁed the indication for reintervention
for a lesion, and therefore the triggers for TLR have to
be interpreted with caution.
Subgroups
Infrapopliteal angioplasty with DEB. Only one case
series reported results of infrapopliteal angioplasty with
DEBs (paclitaxel coated). The patient and lesion character-
istics for this study are outlined in Table II8; 109 limbs with
peripheral arterial disease (PAD: claudication, 17.4%; CLI,
82.6%) were treated. Lesion length was long (mean, 176
mm), and the majority of patients had “complete or
functional” occlusion of all crural vessels (77.1%). The term
functional was not deﬁned. Outcomes are summarized in
Table III. Procedural technical success, deﬁned as aresidual stenosis of the target lesion after angioplasty of less
than 30%, was 95.5%. At 3 months, the primary patency
was 72.6%. After a mean follow-up of 12.3 months, TLR
was 17.3%, wound healing was 74.2%, limb salvage was
achieved in 95.6% of the CLI patients, and mortality was
16%. The study was not designed to investigate primary or
secondary patency out to this time interval.
Femoropopliteal angioplasty with DEB. Four
studies reported results of femoropopliteal angioplasty
with DEB (all paclitaxel coated), three of which were ran-
domized trials comparing DEB with SPTA (Table II)
(claudication, 182; CLI, 12; unclear severity, 48).9-11,30
The 242 limbs with PAD were treated with DEBs. Pro-
cedural technical success was 91.2% (87.7%-100%). As the
number of patients with CLI and in particular tissue loss
was unclear (Tepe et al) or low (Rutherford class 4: 5 of 87,
class 5: 0 of 87 [Werk et al]; class 4: 8 of 105, class 5: 0 of
105 [Micari et al]; class 4: 2 of 91, class 5: 2 of 91 [Werk
et al]), these studies are underpowered to detect differences
in limb salvage or death. After follow-up of 11.0 months
(7.2-12 months), TLR rate was 7.7% (7.1%-10%) and
mortality was 2% (range, 0%-4%). The trials demonstrated a
Table III. Angioplasty with drug-eluting balloon (DEB): Angiographic and clinical outcomes
First
author
Technical
success
Primary
patency,
3 months, %
Primary patency,
6 months,
drug-eluting arm, %
Primary patency,
6 months,
standard arm, %
Primary patency,
1 year, drug-
eluting arm, %
TLR, drug
eluting
arm, %
TLR,
standard
arm, %
Limb salvage rate,
drug-eluting
arm, %
Schmidt8 95.5 72.6 d NA d 17.3 NA 95.6
Tepe9 91.7 83 56 d 10 48 96
Werk10 91.1 94 94 d 7 33 100
Micari11 87.7 d d 83.7 7.6 NA No data
Werk30 100 91 68 7.1 27.9 100
ABPI, Ankle-brachial pressure index; CLI, critical limb ischemia; f/u, follow-up; IC, intermittent claudication; PSVR, peak systolic velocity ratio; SPTA,
standard percutaneous angioplasty; TLR, target lesion revascularization.
Fig 1. Comparison between drug-eluting balloon (DEB) and standard percutaneous balloon angioplasty (SPTA) in the
femoropopliteal segment for binary restenosis rates. Forest plot of pooled results from comparative studies. CI,
Conﬁdence interval; M-H, Mantel-Haenszel.
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(Table III). Tepe et al and Werk et al (2012) clearly
described the use of multiple DEBs for longer lesions, but
lesions requiring further dilation because of residual ste-
nosis >30% were treated with SPTA or BMSs. The study of
Werk et al (2008) was unclear about the type of balloon
used in lesions requiring further dilation.
Meta-analysis of DEB studies. The pooled result of
the three controlled studies comparing DEBs with SPTA
(all in the femoropopliteal segment) demonstrated a statis-
tically signiﬁcant result in favor of DEB for binary primaryrestenosis ($50% of the reference vessel segment) (Fig 1)
and TLR (Fig 2).9,10,30 It was not possible to pool the
results for other angiographic outcomes (Tepe reported
LLL and standard deviation, Werk [2008] reported LLL
and interquartile range, Werk [2012] reported LLL and
95% CI) or clinical outcomes (Tepe reported change in
mean Rutherford class, Werk [2008 and 2012] reported
categorical changes from baseline, Tepe [2008] reported
ankle-brachial pressure index and standard deviation,
Werk reported ankle-brachial pressure index and inter-
quartile range). The event rate was too low to perform a
Limb salvage
rate, standard
arm, %
Rutherford class,
drug-eluting arm
Rutherford class,
standard arm
Change in
Rutherford class
at follow-up
Wound
healing, %
Amputation-free
survival, IC
and CLI Physiologic data
NA 3: 19/109
4: 19/109
5: 70/109
6: 1/109
d Clinical improvement
in 91.2% of limbs
At follow-up: class 0:
61/91; class 1: 6/
91; class 2: 5/91;
class 3: 2/91; class
4: 7/91; class 5:
10/91; class 6: 0/91
74.20 85/104 No data
100 Mean, 3.4 Mean, 3.1 Mean DEB, 1.2;
STPA, 1.6
No data No data ABPI pre: 0.5 DEB,
0.5 SPTA
ABPI f/u: 0.8 DEB,
0.8 SPTA
98 1: 2/45
2: 10/45
3: 31/45
4: 2/45
1: 1/31
2: 7/42
3: 31/42
4: 3/42
Related to baseline:
DEB worsened,
0/45; equal, 8/45;
improved, 26/45;
missing, 11/45
No data 1/45 DEB; 1/42
SPTA
ABPI pre: 0.8 DEB,
0.9 SPTA
ABPI f/u: 0.8 DEB,
0.8 SPTA
1: 1/105
2: 28/105
3: 8/105
4: 8/105
NA 0: 60/92
1: 17/92
3: 13/92
4: 2/92
(derived from graphic
data)
NA 89/92 ABPI pre: 0.56
ABPI f/u: 0.86
PSVR pre: 3.1
PSVR f/u: 1.2.
100 2: 4/44
3: 38/44
4: 0/44
5: 2/44
2: 6/47
3: 39/47
4: 2/47
5: 0/47
Related to baseline:
DEB worsened,
0/44; equal, 8/44;
improved, 32/44;
missing, 4/44
No data 42/42 DEB; 40/43
SPTA
No data
Table III. Continued.
Fig 2. Comparison between drug-eluting balloon (DEB) and standard balloon percutaneous angioplasty (SPTA) in the
femoropopliteal segment angioplasty for target lesion revascularization (TLR). Forest plot of pooled results from
comparative studies. CI, Conﬁdence interval, M-H, Mantel-Haenszel.
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outcomes (amputation: DEB 2 of 137, SPTA 1 of 135;
death: DEB 2 of 137, SPTA 5 of 135).
Infrapopliteal angioplasty with DES. Fifteen studies
reported the results of infrapopliteal angioplasty with DESs
(Table IV); 882 limbs were treated with DESs (claudica-
tion,160; CLI, 590; unclear severity, 132).12-14,16-24,31-33
A variety of coatings were used for the DESs (nine studies
used sirolimus; one, everolimus; three, sirolimus/paclitaxel;
one, sirolimus/everolimus/paclitaxel; one, sirolimus/
zotarolimus/everolimus). Technical success rates of 99.0%(90.7%-100%) were achieved. Mean follow-up was
22.9 months (6.5-47.5 months). TLR rate was 10.8%
(0%-81.1%), limb salvage was achieved in 97.4% (78.8%-
100%) of the CLI patients, and mortality was 17% (range,
0%-32%). Seven studies were comparative (vs either SPTA or
BMS), of which ﬁve were randomized controlled trials. Tepe
and Siabilis had longer clinical follow-up than the other
comparative studies. Differences between DES, BMS, and
SPTA in amputation-free survival were not observed by
Tepe (amputation-free survival: DES 11 of 14, BMS 11 of
16, SPTA 11 of 14). Limb salvage and patient mortality
Table IV. Study design and characteristics of patients and lesions of included studies of angioplasty with drug-eluting
stent (DES)
First author Year Study Patients, No.
Limbs
treated, No. CLI, %
Diabetes
mellitus, %
Renal
insufﬁciency, % TASC
Scheinert12 2006 Cohort with control,
DES vs BMS
60 60 74.6 83.3 43.2 No data
Commeau13 2006 Case series, DES 30 30 86.6 36.6 No data TASC I C
Bosiers14 2006 Case series, DES 18 100 87.3 43.2 No data
Feiring15 2007 Case series, DES 5 5 100 100 100 No data
Rosales16 2008 Case series, DES 24 24 100 83 41 No data
Grant17 2008 Case series, DES 10 10 90 50 d No data
Feiring18 2010 Case series, DES 106 130 100 83.3 10 No data
Lookstein19 2011 Case series, DES 67 67 100 72 43 No data
Rastan20 2012 RCT, DES vs BMS 161 161 46.6 53.8 35.4 No data
Bosiers21 2012 RCT, DES vs BMS 140 140 100 60 30 No data
Scheinert22 2012 RCT, DES vs SPTA 200 200 Unclear 64.6 d No data
Spiliopoulos23 2012 Case series, DES 39 41 100 61.6 5.1 No data
Werner24 2012 Case series, DES 158 158 43.7 65 d No data
Duda25 2002 RCT, DES vs BMS 36 36 No data 50 No data TASC I C
Duda26 2005 RCT, DES vs BMS 57 57 38.9 50 d No data
Dake27 2011 Case series DES 787 787 No data 36.2 No data TASC II
236/900 A
265/900 B
228/900 C
126/900 D
45/900 not
assessed
Dake28 2011 RCT, DES vs BMS 474 474 9 49.2 10.2 No data
Lammer29 2011 Case series DES 104 104 17 39 No data TASC II
44/106 A
48/106 B
14/106 C
0/106 D
Tepe33 2010 RCT, DES vs BMS
and SPTA
44 44 100 65.9 No data No data
Falkowski31 2009 RCT, DES vs BMS 50 50 36 40 No dialysis patients No data
Siablis32 2009 Cohort with control,
DES vs BMS
103 122 100 82 49 No data
BMS, Bare-metal stent; CLI, critical limb ischemia; NA, not applicable; RCT, randomized controlled trial; SPTA, standard percutaneous angioplasty; TASC,
TransAtlantic Inter-Society Consensus.
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Siabilis (limb salvage: DES 80.3% vs BMS 82.0%, P ¼ .507;
and death: DES 29.3% vs BMS 32%, P ¼ .205).32,33 It was
not possible to extract or to derive data on wound healing
for these studies. Table V outlines outcomes for the pub-
lished case series.
Femoropopliteal angioplasty with DES. Six studies
reported results of femoropopliteal angioplasty with DES
(Table IV) (claudication, 301; CLI, 58; unclear severity,
815).15,25-29 A variety of coatings were used for the DESs
(three studies used sirolimus; one, everolimus; two, pacli-
taxel). Three were randomized controlled trials comparing
DESs with BMSs or SPTA; 1174 limbs with PAD were
treated. Technical success was 92.7% (range, 95%-100%).
Mean follow-up was 10.6 months (6-12 months). TLR was10% (0%-20%), limb salvage was achieved in 89% of the
CLI patients, and mortality was 3% (range, 0%-6%).
(Table V). A statistically signiﬁcant decrease in the rate of
TLR was demonstrated in only the two more recent pro-
spective randomized studies (Table V).
Meta-analysis of DES studies. The pooled results of
the comparative studies of DES vs BMS demonstrated a
statistically signiﬁcant result in favor of DES with regard
to binary primary restenosis (Fig 3), TLR (Fig 4), and
LLL (Fig 5) but not amputation (Fig 6) or death (Fig 7).
The observation persisted in subgroup analysis of the
infrainguinal segment (Figs 8 to 12). Only the binary
restenosis rate was improved by DES use in the femo-
ropopliteal segment (Fig 13). The rates of LLL
(OR, 0.22; 95% CI, 0.69 to 0.26; P ¼ .38) and death
Lesion type, drug-eluting arm
Disease length,
drug-eluting arm, mm Lesion type, standard arm
Disease length,
standard arm, mm
Follow-up,
months
All de novo occlusions
6/30
#30 All de novo occlusions
7/30
#30 6.5 angiographic
9.6 clinical
All de novo No data NA NA 7.7 6 5.8
No data No data NA NA 6
All de novo No data NA NA 29 6 8
No data No data NA NA 9.5
No data 24.8 NA NA 12.4 6 6.5
No data No data NA NA 27.4 6 18.6
No data 49.7 NA NA 20
All de novo
No data on occlusions
31 All de novo
No data on occlusions
31 33.9
All de novo occlusions
12/78
15.9 All de novo occlusions
13/76
18.9 12
Mixed de novo, restenotic 6/113
and occlusions 92/113
26.9 Mixed de novo, restenotic 2/115
and occlusions 87/115
26.8 12
All de novo 31.3 NA NA 47.5 6 14.8
Mixed de novo, restenotic
50 (31.6%) and occlusions
41 (31.6%)
$80 NA NA 31.16 6 20.3
Mixed de novo, restenotic and
occlusions (10/18)
82.9 Mixed de novo, restenotic and
occlusions (11/18)
88.6 6
Mixed de novo, restenotic 3
(10%) and occlusions 22 (76%)
86.5 Mixed de novo, restenotic 1 (4%)
and occlusions 16 (57%)
76.3 6
Mixed de novo, restenotic 219
(24.3%), occlusions 345
(38.3%), and in-stent stenosis
130 (14.4%)
99.5
431/900 >70
202/900 >150
NA NA 12
All immediate procedural failure #140 (about 65) All immediate procedural failure #140 (about 65) 12
Mixed de novo, restenotic (9.4%)
and occlusions (45%)
9 NA NA 12
Occlusion 28.6% 27 BMS: occlusion 37.5%
SPTA: occlusion 28.6%
BMS: 35
SPTA: 31
6 angiographic
2-4 years clinical
No data 17 No data 18.2 6
All failed primary SPTA
Occlusion 37/153
45 All failed primary SPTA
Occlusion 27/77
45.18 36
Table IV. Continued.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 6 Canaud et al 1727(OR, 0.42; 95% CI, 0.06-2.97; P ¼ .39) were not different
between groups in the femoropopliteal segment. The TLR
and amputation rates were not compared in the femo-
ropopliteal segment because of the very low event rate for
results to be meaningful (TLR: DES 0 of 47, BMS 0 of 46;
amputation: DES 1 of 61, BMS 2 of 62). It was not
possible to report the results for other clinical outcomes
because of differences in the type or manner in which
outcomes were reported (change in Rutherford class re-
ported as numbers improving, groups before and after
intervention, median or not provided; only two studies
reported ankle-brachial pressure index data, and one re-
ported transcutaneous partial pressures of oxygen). When
we restricted our analysis to only randomized controlled
trials (removing the two infrapopliteal cohort studies withcontrols), the overall pooled and infrapopliteal subgroup
results were unchanged:
Pooled DES vs BMSdbinary restenosis: OR, 0.16; 95%
CI, 0.09-0.30; P < .0001; TLR: OR, 0.26; 95% CI, 0.14-
0.48; P < .0001; amputation: OR, 0.31; 95% CI, 0.06-
1.56; P¼ .16; death: OR, 1.02; 95% CI, 0.57-1.82; P¼ .95.
Infrapopliteal DES vs BMSdbinary restenosis: OR,
0.12; 95% CI, 0.05-0.28; P < .0001; TLR: OR, 0.25;
95% CI, 0.13-0.47; P < .0001; amputation: OR, 0.31;
95% CI, 0.06-1.56; P ¼ .16; death: OR, 1.02; 95% CI,
0.57-1.82; P ¼ .95.
DISCUSSION
This systematic review and meta-analysis has demon-
strated that DESs and DEBs have encouraging technical
Table V. Angioplasty with drug-eluting stent (DES): angiographic and clinical outcomes
First
author
Technical
success
Patency,
6 months,
drug-eluting
arm, %
Patency,
6 months,
standard
arm, %
Patency,
1 year, drug-
eluting arm, %
Patency, 1 year,
standard
arm, %
Patency, 2 years,
drug-eluting
arm, %
TLR,
drug-eluting
arm, %
TLR,
standard
arm, %
Limb salvage
rate, drug-
eluting arm, %
Limb salvage
rate, standard
arm, %
Scheinert12 100 d d 100 65 d 0 23.3 100 90
Commeau13 100 d NA 97 NA d 0 NA 100 NA
Bosiers14 100 d d d d d 0 94 NA
Feiring15 100 d NA 100 NA d NA 0 100 NA
Rosales16 96 d NA 89.4 NA d NA 0 84 NA
Grant17 100 d NA 90 NA d NA 10 100 NA
Feiring18 90.7 d NA 92.4 NA d NA 15 95 NA
Lookstein19 100 90 86 72 d 91.1 NA
Rastan20 No data No data No data No data No data No data 9.2 12.9 97.4 87.1
Bosiers21 100 d d 85 84 d 9 35 98.6 96.9
Scheinert22 95.5 d d 77.6 57.1 d 10 16.6 86.2 80
Spiliopoulos23 100 d NA 73.6 NA 42.7 8 at 1 year At 1 year, 84.3
Werner24 100 d d 87 NA 85 0 At 1 year, 93.3
At 2 years, 78.8
NA
Duda25 100 100 58.9 d d 0 0 0 100 100
Duda26 100 100 93 d d 0 0 0 100 100
Dake27 97.6 d d 86.2 NA 9.5 NA No data NA
Dake28 95 d d 83.1 32.8 d 9.5 17.5 100 100
Lammer29 98 94 d 68 NA d 30 NA d NA
Tepe33 100 91 33 (BMS),
25 (SPTA)
d d d 7 14 (BMS)
15 (SPTA)
93 86 (BMS)
84 (SPTA)
Falkowski31 100 16 19 d d d 12 14 100 100
Siablis32 96 d d d d 3 years: DES 32.9,
BMS 17.1
81.1 96.3
ABPI, Ankle-brachial pressure index; BMS, bare-metal stent; CLI, critical limb ischemia; f/u, follow-up; IC, intermittent claudication; NA, not applicable;
TLR, target lesion revascularization.
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Rutherford class,
drug-eluting arm
Rutherford class,
standard arm
Change in
Rutherford
class at follow-up
Wound
healing, %
Amputation-free
survival,
IC and CLI
Physiologic data
3: 11/30
4: 8/30
5: 11/30
3: 10/30
4: 11/30
5: 9/30
Assisted improvement by 1 class,
22/30 DES and 18/30 BMS
No data Not able to calculate No data
3: 4/30
4: 16/30
5: 7/30
6: 3/30
NA 0: 19/28
1: 2/28
2: 6/28
5: 1/28
9/10 28/30 No data
4: 12/18
5: 4/18
6: 2/18
NA 95.7% < class 3 No data 94.1 No data
4: 2/5
5: 3/5
NA 5/5 < class 4 3/3 5/5 ABPI pre: 0.32
ABPI f/u: 0.58
Toe pressure pre: 21 mm Hg
Toe pressure f/u: 46 mm Hg
24/24 > class 3 NA No data No data 20/24 No data
Fontaine class
IIb: 1/10
III: 4/10
IV: 5/10
NA No data No data 10/10 No data
4: 45/118
5: 36/118
6: 37/118
NA Improved at follow-up (healed/
relief of rest pain), 104/111
68/74 68/118 (derived from
graphic data)
No data
4: 14/67
5: 42/67
6: 11/67
NA No data No data 88 No data
3: 40/82
42/82 $ class 4
3: 46/79
33/79 $ class 4
0/44 worse by 1 class
7/44 no change DES
2/44 worse by 1 class
15/44 no change BMS
No data Not able to calculate No data
4: 37/74
5: 37/74
4: 26/66
5: 40/66
DES: class 0: 26/53; class 1: 6/
53; class 2: 5/53; class 3: 4/53;
class 4: 5/53; class 5: 5/53;
class 6: 2/53
BMS: class 0: 20/45; class 1: 5/
45; class 2: 6/45; class 3: 7/45;
class 4: 0/45; class 5: 6/45;
class 6: 1/45
No data Not able to calculate No data
Mean, 4.1 NA Improvement in Rutherford class:
DES 54/71 and SPTA 51/76
No data Not able to calculate No data
4: 29/41
5: 9/41
6: 3/4
NA Not speciﬁed No data 33/39 No data
3: 89/158
4: 19/158
5: 32/158
6: 18/158
NA Sustained improvement by at least
1 Rutherford category in 59/
77 claudicants and 54/59
patients with CLI
No data 63% claudicants and
41% CLI patients
No data
1-2: 7/18
3-4: 11/18
1-2: 12/18
3-4: 6/18
No numerical data regarding
changes in Rutherford class
NA 100% No data
0-2: 13/29
3-4: 16/29
0-2: 14/28
3-4: 14/28
DES: class 0: 23/24;
class 1-2: 1/24
BMS: class 0: 18/26; class 1-2: 7/
26; class 3-4: 1/26
NA 27/29 DES;
27/28 BMS
ABPI pre: 0.67 DES, 0.61 BMS
ABPI f/u: 0.92 DES, 0.88 BMS
Median Rutherford
class, 3
NA Median, 0 No data No data ABPI pre: 0.6
ABPI f/u: 0.9
About 10% CLI About 10% CLI Not provided for subgroups of
interest for meta-analysis
Not provided for
subgroups of interest
for meta-analysis
Not provided for
subgroups of interest
for meta-analysis
No data
2: 36/104
3: 52/104
4: 9/104
5: 9/104
d Sustained beneﬁt by at least 1 class
in 83/104
No data 16/18 in CLI patients ABPI pre: 0.64
ABPI f/u: 0.89
5-6: 14/14 5-6: 16/16 (BMS)
5-6: 14/14 (SPTA)
2- to 4-year follow-up:
DES 9/11 < class 4
BMS 8/11 < class 4
SPTA 6/11 < class 4
2- to 4-year follow-up:
DES 9/11
BMS 8/11
SPTA 6/11
2- to 4-year follow-up:
DES 11/14
BMS 11/16
SPTA 11/14
Toe pressure before intervention
and at 6 months:
DES 18 to 25 mm Hg
BMS 20 to 40 mm Hg
SPTA 15 to 30 mm Hg
3: 16/25
4: 6/25
5: 3/25
3: 18/25
4: 4/25
5: 3/25
6-month data not provided No data 100 ABPI pre: DES 0.5, BMS 0.5
ABPI f/u: DES 0.7, BMS 0.6
4: 26/62
5: 26/62
6: 10/62
4: 15/41
5: 16/41
6: 10/41
No data No data Not able to calculate No data
Table V. Continued.
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Fig 3. Pooled infrainguinal comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty for
binary restenosis rates. Forest plot of pooled results from comparative studies. For Dake 2011, only the subgroup that
randomized patients to either DES or BMS after failed standard balloon percutaneous angioplasty (SPTA) was used in
the analysis. CI, Conﬁdence interval; M-H, Mantel-Haenszel.
Fig 4. Pooled infrainguinal comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty for
target lesion revascularization (TLR). Forest plot of pooled results from comparative studies. CI, Conﬁdence interval;
M-H, Mantel-Haenszel.
Fig 5. Pooled infrainguinal comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty for
late lumen loss (LLL, mm). Forest plot of pooled results from comparative studies. CI, Conﬁdence interval; IV, inverse
variance; SD, standard deviation.
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However, longer term follow-up and better designed ran-
domized trials (allocation concealment/blinding) with
more patient-centered and focused outcomes (including
amputation-free survival) in patients with CLI are really
required before the technology can be recommended foreveryday clinical practice. Similar initial excitement about
other endovascular technologies for PAD, such as laser
atherectomy, has failed to transfer to routine mainstream
practice because of lack of evidence.34
Drug-eluting devices for treatment of PAD ﬁrst used
in the femoropopliteal segment initially failed to demonstrate
Fig 6. Pooled infrainguinal comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty for
amputation. Forest plot of pooled results from comparative studies. CI, Conﬁdence interval; M-H, Mantel-Haenszel.
Fig 7. Pooled infrainguinal comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty for
death. Forest plot of pooled results from comparative studies. For Dake 2011, only the subgroup that randomized
patients to either DES or BMS after failed standard balloon percutaneous angioplasty (SPTA) was used in the analysis.
CI, Conﬁdence interval; M-H, Mantel-Haenszel.
Fig 8. Comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty in the infrapopliteal
segment for binary restenosis rates. Forest plot of results from comparative studies. CI, Conﬁdence interval;
M-H, Mantel-Haenszel.
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rates.25,26 One potential explanation for these initial poor
results may be inadequate drug delivery (90 mg siroli-
mus/cm2 stent area) and that the stent platform was prone
to fracture (18% at 6 months). Recently presented 3-yearTLR rates favor DES over BMS angioplasty (83% vs
70.2%, respectively).28 The prevalence of stent fracture
rates at 12 months was only 0.4%. The Superﬁcial Femoral
Artery Treatment with Drug-Eluting Stents (STRIDES)
study was a prospectively collected case series describing
Fig 9. Comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty in the infrapopliteal
segment for target lesion revascularization (TLR). Forest plot of results from comparative studies. CI, Conﬁdence
interval; M-H, Mantel-Haenszel.
Fig 10. Comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty in the infrapopliteal
segment for late lumen loss (LLL, mm). Forest plot of results from comparative studies. CI, Conﬁdence interval;
IV, inverse variance; SD, standard deviation.
Fig 11. Comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty in the infrapopliteal
segment for amputation. Forest plot of results from comparative studies. CI, Conﬁdence interval; M-H, Mantel-
Haenszel.
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are noteworthy, given that the initial favorable primary
patency rate of 94% at 6 months was not sustained at
12 months (68%). It is difﬁcult to conclude, therefore,
that the everolimus-eluting peripheral DES represents a
signiﬁcant advance in currently available interventional
technology. The lack of efﬁcacy cannot be explained by
the stent platform (no stent fracture reported), but it
may still be explained by either inadequate drug delivery
or the coating used.
The management of patients with infrapopliteal disease
is historically challenging. Diabetes and renal failure are
more common in these patients, and consequently angio-
graphically difﬁcult long calciﬁed lesions are more frequent.A recent systematic review of balloon angioplasty for
below-the-knee arteries demonstrated a 1-year primary
patency rate between 33% and 37%.35 Two randomized
controlled trials failed to show the superiority of primary
infrapopliteal stenting over balloon angioplasty alone.36,37
Despite the introduction of drug-eluting devices with a
great deal of expectation, this review highlights that the ev-
idence for clinical as opposed to angiographic superiority is
at present lacking. There are currently three randomized
trials under way to evaluate the beneﬁts of DEBs in the
infrapopliteal segment: DEBATE-BTK (primary outcome
measure: binary restenosis; interim results: 27% DEB,
56% SPTA; study completion expected November 2013);
IN.PACT DEEP (primary outcome measures: LLL, TLR,
Fig 12. Pooled infrainguinal comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty in
the infrapopliteal segment for death. Forest plot of results from comparative studies. CI, Conﬁdence interval;
M-H, Mantel-Haenszel.
Fig 13. Comparison between drug-eluting stent (DES) and bare-metal stent (BMS) angioplasty in the femoropopliteal
segment for binary restenosis rates. Forest plot of results from comparative studies. CI, Conﬁdence interval;
M-H, Mantel-Haenszel.
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pected primary completion August 2013; expected study
completion August 2017); and EURO CANAL (outcome
measures: LLL, amputation-free survival, TLR; temporarily
stopped recruiting). Preliminary results from IN.PACT
demonstrate a primary restenosis rate >50% after 3 months
in 69% of patients treated with SPTA and only 31% of pa-
tients treated with DEB.38 Clinical improvement is evident
in 36 of 48 patients (75%) in the DEB group. Of these tri-
als, only EURO CANAL is looking at amputation-free sur-
vival as a primary outcome. This is unfortunate as this is the
most clinically relevant and therefore useful outcome. The
emphasis in the other trials is still on radiologic primary
outcomes, and therefore they are unlikely to signiﬁcantly
add to our understanding of the effectiveness, or not, of
drug-eluting technology.
The use of DESs for infrapopliteal angioplasty is better
reported. The ﬁve randomized controlled trials all demon-
strate a statistically signiﬁcant decrease in the rate of TLR.
However, to date, only one prospective randomized study
has evaluated the use of DESs for long (>7 cm) infrapopli-
teal lesions and demonstrated signiﬁcantly better primary
patency rate at 13.1 months.9 The two comparative studies
with the longest follow-up did not demonstrate a reduction
in limb loss or survival with DESs.32,33
The early enthusiasm for use of drug-eluting devices
in infrainguinal vessels was tempered by the results ofseveral small negative studies.26,29 However, new trials,
using modiﬁed stent platforms, DEBs, or variations of
type and dosage of drug, suggest that drug-eluting tech-
nology may reduce restenosis rates. This meta-analysis
demonstrated a statistically signiﬁcant impact in favor of
DEB to STPA for binary primary restenosis and TLR
and in favor of DES to BMS in regard to TLR, binary pri-
mary restenosis rate, and LLL. However, it was not
possible to pool the results for other angiographic or clin-
ical outcomes because of differences in the type of out-
comes or the manner in which they were reported.
Many of these studies have drawbacks (short mean lesion
length, short-term follow-up). Most studies presented
pooled data from patients with intermittent claudication,
rest pain, and tissue loss as well as from patients with
and without diabetes. These represent signiﬁcantly
different prognostic groups, and therefore healthy inter-
pretation of results is challenging. Many questions about
the use of drug-eluting devices for PAD remain to be
answered. It will be important for future studies to be
designed and powered to address the more fundamental
question of whether drug-eluting technology improves
clinical outcomes, such as amputation-free survival. The
potential beneﬁt of drug-eluting devices for certain lesions
and patient subgroups, such as in-stent restenosis and dia-
betic patients, will need to be determined before wide-
spread primary application can be recommended.
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there to be trials with long-term follow-up in patients with
diabetes, in whom the treatment is more complex.39 Pa-
tients with predominantly neuropathic ulceration as
opposed to ischemic ulceration will heal with good foot
care irrespective of whether they are “revascularized.”
The TransAtlantic Inter-Society Consensus II guidelines
for the management of PAD identify a transcutaneous par-
tial pressure of oxygen of <30 mm Hg for diagnosis of a
critically ischemic limb. The International Working Group
on the Diabetic Foot guidelines state that wound healing is
likely if the transcutaneous partial pressure of oxygen is
>50 mmHg. Unfortunately, very few studies including pa-
tients with diabetes and classifying patients with tissue loss
reported physiologic data either before or after interven-
tion. It is therefore difﬁcult to judge what proportion of
these patients with diabetes had true Rutherford-Baker
category 5 or 6 ischemia as opposed to neuropathic ulcers
with adequate tissue perfusion. Future trials of drug-eluting
technology should report in detail toe pressures, transcuta-
neous partial pressure of oxygen, and ulcer grading both
before and after intervention in patients with diabetes.
Indeed, given the predicted magnitude of the problem, it
would be prudent to undertake some trials exclusively in
diabetic patients with tissue loss and proven critical
ischemia.
On the basis of literature review, the U.K. National
Institute for Health and Clinical Excellence guidelines for
lower limb PAD diagnosis and management have stated
that this technology should not normally or routinely be
used outside a trial situation. The results of our review,
which includes nine additional studies with controls, agree
with this conclusion.
There was wide variation in the duration of dual anti-
platelet therapy used by the included studies. This is a
reﬂection of the lack of consensus by vascular specialists.
In coronary disease, current guidelines recommend 6 to
12 months of dual antiplatelet therapy when DESs are
used.40
Only 15% of the stented surface in DESs is covered by
struts, which limits effective local drug delivery and leads to
incomplete endothelialization. To overcome this issue,
DEBs coated with antiproliferative pharmaceuticals were
introduced.41,42 The duration of inhibition of cell prolifer-
ation far exceeds the time during which the cells are actu-
ally exposed to the drug. The cost-effectiveness of DEBs is
also under intense scrutiny, as they are designed for single-
site inﬂation only; some long lesions may require multiple
inﬂations, requiring multiple DEBs or additional stenting,
dramatically increasing cost of the procedure. There is no
consensus as to how some of these devices should be
used. Formal cost-effectiveness analysis of DEB and DES
use has not been reported.
This systematic overview of best evidence has several
limitations. Differences in the drug type and dosage add
complexity to the interpretation of outcomes of studies
using drug-eluting technology. Because of the relatively
small number of studies, we were unable to undertake ameaningful subgroup analysis of the inﬂuence of different
drug coatings on outcome. There was a wide variation in
reporting of patient characteristics and in deﬁnitions of
outcome. These factors limited the type of meta-analysis
that could be performed. Therefore, the importance of us-
ing common standards to report results of treatment for
PAD and, especially, for endovascular treatment of infrain-
guinal lesions to facilitate future analyses must be
stressed.43,44 Future trials should separate patients with
claudication and critical ischemia. In critically ischemic pa-
tients, detailed assessment of physiologic parameters is
required. Patients with diabetes should be analyzed in
detail as a subgroup or be assessed in separate trials. For pa-
tients with claudication, the primary outcomes of interest
are changes in walking distance and quality of life, which
should be assessed formally. For patients with critical
ischemia, the primary outcomes of interest are wound heal-
ing and amputation-free survival. At present, end points
such as TLR are subjective and ill-deﬁned. In future trials,
separate prespeciﬁed deﬁnitions will be required for claudi-
cation, CLI, and diabetic foot ulcers if they area included as
secondary end points. Trials of drug-eluting technology in
claudicants should be restricted to the femoropopliteal
segment. In patients with critical ischemia, multilevel dis-
ease is the norm. We therefore do not recommend separate
suprapopliteal and infrapopliteal studies. At present, trials
should focus on comparing stents and balloons separately.
Cost-effectiveness analysis should be incorporated into
future trial designs.
CONCLUSIONS
Studies to date suggest that the concept of drug-
eluting endovascular technology holds promise. However,
data are sparse and have serious limitations, including po-
tential bias secondary to failure of adequate blinding, use
of predominantly radiographic outcomes, relatively short
follow-up, relatively small numbers of patients with CLI,
and poor representation of patients with diabetes. The
management of patients with CLI and diabetes is different
from that of the general population and arguably more
complex. Separate studies should be designed and imple-
mented to elucidate outcomes in this growing group of pa-
tients.40 The cost-effectiveness of this technology has not
been adequately addressed in the literature. Further large
and therefore adequately powered randomized controlled
trials with long-term follow-up, carefully designed method-
ology, and robust reporting on clinical outcomes are
required before this technology can be considered superior
to plain old balloon angioplasty.
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